Common Contracts
1 similar Collaboration and Co-Development Agreement contracts
Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royaltiesCollaboration and Co-Development Agreement • February 24th, 2023
Brighton, United Kingdom - 24 February 2023 - desuny pharma plc (AI M: d EST), a clinical stage innovauve biotechnology company focused on the development of novel medicines that can prevent life-threatening infecuons, is pleased to announce that it has signed an exclusive collaborauon and co-development agreement for the North American (U.S., Canada and Mexico) rights of NTCd-M3, its lead asset for the prevenuon ofClostridioides difficile infecuon (Cd I ) recurrence, with Sebela pharmaceuticals®, a U.S. pharmaceutical company with a market-leading position in gastroenterology.
